Year: 2022

MONT-SAINT-GUIBERT, Belgium, Dec. 21, 2022 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today provides an update on its Celyad 2.0 business strategy which has been adopted and implemented over the last few months. In keeping with this strategy, the Company intends to focus on maximizing its valuable intellectual property (IP) estate, and strengthening its research focus.The Company has compiled a foundational and broad IP estate that controls key aspects of developing therapies in the allogeneic cell therapy space. The patents around allogeneic CAR T-cell therapies and NKG2D-based therapies provide an avenue to develop intellectual property programs...

SAN JOSE, California, December 21, 2022 — Ensurge Micropower (OSE: ENSU, and OTCIQ: ENMPY), today announced it has received the first production order for 150,000 units of its rechargeable 1-100 milliampere (mAh) solid-state lithium microbattery, a customized version based on the packaged battery it has been sampling to multiple manufacturers and potential strategic partners. Ensurge expects additional orders in 2023 and beyond from this lead customer, an innovator in the digital health market. “This significant milestone validates Ensurge’s strategic value propositions and unique differentiation of our technology,” said Kevin Barber, Ensurge Chief Executive Officer. “This major milestone follows our successful sampling of both unit-cell and packaged microbattery samples to multiple manufactures and potential strategic partners....

Multitude SE decides to further postpone relocation to Germany Helsinki, 21 December 2022 – Multitude SE (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude” or the “Group”) announces that the board of directors of Multitude has resolved to further postpone the relocation of Multitude’s registered office from Finland to Germany. The board of directors of Multitude cannot at this time give an estimate on how long the further postponement will be but notes that their firm intention still is to pursue the relocation in future. The postponement is due to continued uncertainties in applicability of certain administrative requirements to Multitude. The contemplated relocation was governed by the transfer proposal in accordance with Article 8(2) of the regulation on the statute for a European company (SE) (2001/2157/EC) approved by the board...

WISeKey Re-affirms its 2023 Growth Forecast; Expects to Exceed FY 2022 Revenue Guidance due to Steady Demand for Semiconductors Projects FY 2022 revenue of over $24.5 million, an increase of more than 10% as compared to FY 2021, despite divestiture of arago GmbH Semiconductors order growth accelerates; backlog of $36 million for IoT Semiconductor products stretches into 2024 and pipeline of opportunities totals $100 million ZUG, Switzerland – December 21, 2022: Ad-Hoc announcement pursuant to Article 53 of SIX Listing Rules – WISeKey International Holding Ltd (NASDAQ: WKEY / SIX: WIHN) (“WISeKey” or the “Company”), a leading Swiss cybersecurity and IoT company re-affirmed its fiscal 2022 revenue forecasts as it reported solid 2022 revenue results of over $24.5 million, an increase of more than 10% compared to FY 2021, due to steady semiconductors...

So far in December, Vow ASA (“Vow”) subsidiary C.H. Evensen AS (CHE), a specialist in heat treatment solutions, has been awarded five large orders for advanced technology to leading industry players. The orders have a combined value of NOK 57 million. The two larger orders, each valued at around NOK 20 million, are for a hot-dip galvanising system to an unnamed customer in Northern Ireland and an unnamed Swedish customer in metals manufacturing. The other three orders are for ThyssenKrupp in Germany, and unnamed customers in Sweden and Norway. “We are experiencing strong demand for our state-of-the-art technology from energy intensive industrial sectors, such as manufacturing and metals production. With soaring energy costs and a growing demand for low-carbon solutions, our solutions are seen as instrumental to improve cost efficiency,”...

FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 10,350,000 shares of its common stock at a public offering price of $7.25 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be approximately $75.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. In addition, Terns has granted the underwriters...